X4 Pharmaceuticals Plans A 25-Patient Trial To Cut Neutropenia Patients' G-CSF Doses, Starting In First Quarter Of 2027

X4 also set topline data for its pivotal 4WARD trial in the first quarter of 2028, with possible FDA approval in late 2028 or early 2029.

Share
X4 Pharmaceuticals Plans A 25-Patient Trial To Cut Neutropenia Patients' G-CSF Doses, Starting In First Quarter Of 2027

X4 Pharmaceuticals, which develops treatments for rare blood diseases, plans to dose its first patient in a new Phase 2b trial called 4STEPS in the first quarter of 2027, according to the presentation it gave at its virtual Investor Day on Thursday. The study will test whether patients with chronic neutropenia can lower or stop their G-CSF injections once its pill, mavorixafor, is added.

A trial built to wean patients off injections

4STEPS is a single-arm, open-label study planning about 25 patients at about 25 sites in the U.S. and UK. Participants must be on stable G-CSF therapy, the injected standard treatment, with a baseline neutrophil count of at least 1,000 cells/µL. Topline data are expected in the first half of 2028.

The design runs four weeks on G-CSF alone, then eight weeks with mavorixafor added, then 16 to 20 weeks of stepwise G-CSF cuts of at least 25%, 50% and 75%, ending in full cessation. A neutrophil-count rule governs each step: at 1,000 or above the dose is reduced, and below 500 it is increased.

The main efficacy measures, taken at six months, are the share of patients who stop G-CSF, the reduction in average daily dose, and the share achieving a cut of at least 75%.

Baseline picture from the pivotal 4WARD study

Blinded, pooled data from the pivotal Phase 3 4WARD trial, as of September 2026, show a median age of 36 and 70% women. Median neutrophil count was 483 cells/µL, 68% of patients had three or more infections at baseline, and severity split evenly between moderate and severe disease. Some 37% were on concurrent G-CSF.

The company expects full enrollment of 126 patients by the end of the fourth quarter of 2026 and topline data in the first quarter of 2028. It anticipates potential FDA approval in primary chronic neutropenia in late 2028 or early 2029. These timelines did not appear in the company's earlier 8-K filings, including the one filed September 9, which did carry the expectation of cash runway into 2029 and U.S. patent protection through 2038.

Market case and the company's footing

X4's only approved product is Xolremdi, mavorixafor, sold in the U.S. for WHIM syndrome, a rare inherited immune disorder. The company's focus is expanding it into primary chronic neutropenia, where it says no oral product is approved. It had $253.0 million in cash and securities at the end of 2025.

The presentation cites a Komodo claims analysis putting about 6,300 primary chronic neutropenia patients in U.S. hospitals in 2025, with a mean stay of about four days per infection. It sizes the base-case U.S. population at about 15,000 symptomatic patients with two or more infections, and about 30,000 with one or more.

XFOR shares traded at $3.46 in Thursday trading, up about 3% from the prior close of $3.35.

Full enrollment in 4WARD is targeted for the end of the fourth quarter of 2026, with the first 4STEPS patient visit following in the first quarter of 2027.

Sources

More on X4 Pharmaceuticals

All X4 Pharmaceuticals (XFOR) coverage →